PHARMACY

PatientPoint names CEO

BY Antoinette Alexander

ORLANDO, Fla. PatientPoint, whose core offering is a self-service kiosk that automates check-in and check-out processes in retail clinic environments and physician offices, has named Raj Toleti CEO.

Previously, Toleti founded Galvanon, a technology company focused on improving the patient experience, which was acquired by NCR in 2005. While at Galvanon, he oversaw the introduction of the first commercially available patient self-service kiosk and software platform to automate patient check-in and intake processes at hospitals and physician offices.

In other company news, PatientPoint has inked new contracts with five organizations: Florida Cardiology, Southlake Orthopaedics, University Internal Medicine and Diabetes Associates, Clara Roman, M.D., and BillingNetwork.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Merck gets nod from FDA for Dulera

BY Alaric DeArment

WHITEHOUSE STATION, N.J. The Food and Drug Administration has approved a new drug by Merck for treating asthma in patients ages 12 years and older, Merck said Thursday.

The FDA approved Dulera (mometasone furoate and formoterol fumarate dihydrate), an inhaled, fixed-dose combination asthma treatment.

“Despite the advances made in the treatment of asthma in recent years, many patients may still not be well-controlled on their current therapies,” University of Tennessee Health Science Center medical professor Michael Blaiss said in a statement on behalf of Merck. “Asthma control is an important treatment goal, and Dulera provides a new option for physicians to help manage this chronic condition in appropriate patients.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves Mylan’s version of Procardia XL

BY Alaric DeArment

PITTSBURGH The Food and Drug Administration has approved a generic drug made by Mylan for heart disease, Mylan said Thursday.

Mylan announced the approval of nifedipine extended-release tablets in the 30, 60 and 90 mg strengths. The drug is used to treat hypertension and angina.

The drug is a generic version of Pfizer’s Procardia XL. Branded and generic versions of the drug had sales of around $234 million during the 12-month period ended in March, according to IMS Health.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES